B7-1/CD80 Antibody [Unconjugated]

Western blot shows lysates of Daudi human Burkitt's lymphoma cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human B7-1/CD80 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF140) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for B7-1/CD80 at approximately 60 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

B7-1/CD80 was detected in immersion fixed paraffin-embedded sections of human tonsil using Goat Anti-Human B7-1/CD80 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF140) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes in germinal center. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: WB, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

B7-1/CD80 Antibody [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human B7-1/CD80
  Extracellular domain
• Specificity: Detects human B7-1/CD80 in direct ELISAs and Western blots. In Western blots, approximately 5% cross-reactivity with recombinant human B7-2 and recombinant mouse B7-2 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CD80
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-1/CD80 Antibody [Unconjugated]

• Activation B7-1 antigen
• B7
• B71
• B7-1
• BB1
• CD28LG1
• CD28LGB7-1 antigen)
• CD80 antigen
• CD80 molecule
• CD80
• costimulatory factor CD80
• costimulatory molecule variant IgV-CD80
• CTLA-4 counter-receptor B7.1
• T-lymphocyte activation antigen CD80

Background

B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the
down‑regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up‑regulated through IFN-gamma . B7-1 and B7-2 are both members of the Immunoglobulin superfamily. Human B7-1 is a 288 amino acid (aa) protein containing a 34 aa signal peptide, a 208 aa extracellular domain, a 21 aa transmembrane domain, and a 25 aa cytoplasmic domain. Human B7-1 and B7-2 share 26% amino acid identity. Human and mouse B7-1 share 44% amino acid identity. However, it has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form theB7-1/B7-2/CD28/CTLA-4 critical binding sites.

1. Azuma, M. et al. (1993) Nature 366:76.
2. Freeman, G.J. et al. (1993) Science 262:909.
3. Freeman, G. et al. (1991) J. Exp. Med. 174:625.
4. Selvakumar, A. et al. (1993) Immunogenetics 38:292.
5. Chen, C. et al. (1994) J. Immunol. 152:4929.
6. Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for B7-1/CD80 Antibody (AF140)(13)

Publications using AF140

• P Chen, Y Chen, M Jiang, Y Mo, H Ying, X Tang, J Zhang Usefulness of the cytokines expression of Th1/Th2/Th17 and urinary CD80 excretion in adult-onset minimal change disease PeerJ, 2020-09-08;8(0):e9854. 2020-09-08 [PMID: 33194357] (IHC, Human)
• T Hirano, S Ohkouchi, N Tode, M Kobayashi, M Ono, T Satoh, Y Mitsuishi, A Watanabe, M Tabata, T Irokawa, H Ogawa, H Sugiura, T Kikuchi, K Akasaka, R Tazawa, Y Inoue, K Nakata, H Kurosawa, M Ichinose Peripheral alveolar nitric oxide concentration reflects alveolar inflammation in autoimmune pulmonary alveolar proteinosis ERJ Open Res, 2018-03-23;4(1):. 2018-03-23 [PMID: 29577041] (ICC, Human)
• P Ai, Z Li, Y Jiang, C Song, L Zhang, H Hu, T Wang Tumor microenvironment contributes to Epstein-Barr virus anti-nuclear antigen-1 antibody production in nasopharyngeal carcinoma Oncol Lett, 2017-06-22;14(2):2458-2462. 2017-06-22 [PMID: 28781683] (IHC-P, Human)
• Herrera M, Soderberg M, Sabirsh A et al. Inhibition of T-cell activation by CTLA4-Fc is sufficient to ameliorate proteinuric kidney disease Am. J. Physiol. Renal Physiol. 7/20/2016 [PMID: 27440778]
• Marianne Delville, Emilie Baye, Antoine Durrbach, Vincent Audard, Tomek Kofman, Laura Braun et al. B7–1 Blockade Does Not Improve Post–Transplant Nephrotic Syndrome Caused by Recurrent FSGS Journal of the American Society of Nephrology 8/1/2016 [PMID: 26701979]
• Marianne Delville, Emilie Baye, Antoine Durrbach, Vincent Audard, Tomek Kofman, Laura Braun et al. B7–1 Blockade Does Not Improve Post–Transplant Nephrotic Syndrome Caused by Recurrent FSGS Journal of the American Society of Nephrology 2016-08-01 [PMID: 26701979] (Immunohistochemistry, Human)
• Elena Gagliardini, Rubina Novelli, Daniela Corna, Carlamaria Zoja, Barbara Ruggiero, Ariela Benigni et al. B7–1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy Journal of the American Society of Nephrology 4/1/2016 [PMID: 26319246]
• Ishimoto T, Cara-Fuentes G, Wang H et al. Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes. Pediatr Nephrol 5/21/2013 [PMID: 23689904]
• Mulder DJ, Pooni A, Mak N, Hurlbut DJ, Basta S, Justinich CJ Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis. Am. J. Pathol., 2011-02-01;178(2):744-53. 2011-02-01 [PMID: 21281807] (IHC-P, Human)
• Garin EH, Mu W, Arthur JM Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int., 2010-05-19;78(3):296-302. 2010-05-19 [PMID: 20485332] (Western Blot, Human)
• Kuhne M, Erben U, Schulze-Tanzil G, Kohler D, Wu P, Richter FJ, John T, Radbruch A, Sieper J, Appel H HLA-B27-restricted antigen presentation by human chondrocytes to CD8+ T cells: potential contribution to local immunopathologic processes in ankylosing spondylitis. Arthritis Rheum., 2009-06-01;60(6):1635-46. 2009-06-01 [PMID: 19479861] (Flow Cytometry, Human)
• Sakthivel P, Shively V, Kakoulidou M The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm. J. Intern. Med., 2007-04-01;261(4):399-407. 2007-04-01 [PMID: 17391115] (ELISA Development, Human)
• Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P Induction of B7-1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest., 2004-05-01;113(10):1390-7. 2004-05-01 [PMID: 15146236] (IHC-Fr, Human)

Bioinformatics

• Gene Symbol: CD80